Immatics (IMTX) Intangibles (2019 - 2025)
Immatics (IMTX) posted Intangibles of $1.8 million for Q4 2025, up 0.91% sequentially from $1.8 million in Q3 2025, and up 5.79% YoY from $1.7 million in Q4 2024.
Immatics (IMTX) Intangibles (2019 - 2025) Analysis & Trends
Immatics has reported Intangibles for 7 years, with the latest figure at $1.8 million in Q4 2025.
- Quarterly Intangibles rose 5.79% year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.8 million (up 5.79% YoY) and the FY2025 annual result came in at $1.8 million, up 1.37% from the prior year.
- Intangibles climbed to $1.8 million in Q4 2025 per IMTX's latest filing, from $1.8 million in the prior quarter.
- Over five years, Intangibles peaked at $3.3 million in Q4 2023 and troughed at $1.1 million in Q1 2021.
- A 5-year average of $1.7 million and a median of $1.7 million in 2023 frame the typical range for Intangibles.
- The sharpest annual moves came in 2023 and 2024: Intangibles soared 101.1% in 2023, then tumbled 48.01% in 2024.
- Over 5 years, Intangibles stood at $1.5 million in 2021, then climbed by 10.68% to $1.7 million in 2022, then surged by 101.1% to $3.3 million in 2023, then sank by 48.01% to $1.7 million in 2024, then advanced by 5.79% to $1.8 million in 2025.
- According to Business Quant data, Intangibles over the past three periods registered $1.8 million, $1.8 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.84 Mn |
| Sep 30, 2025 | 1.82 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 1.68 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.63 Mn |
| Dec 31, 2023 | 3.35 Mn |
| Sep 30, 2023 | 1.78 Mn |
| Jun 30, 2023 | 1.80 Mn |
| Mar 31, 2023 | 1.68 Mn |
| Dec 31, 2022 | 1.67 Mn |
| Sep 30, 2022 | 1.55 Mn |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 1.44 Mn |
| Dec 31, 2021 | 1.50 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Jun 30, 2021 | 1.52 Mn |
| Mar 31, 2021 | 1.11 Mn |